H. Wang

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.

R. Ling, L. Wang, Q. Yao, 2015, Genetics and molecular research : GMR.

Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim report.

W. Curran, S. Litwin, B. Movsas, 2001, Clinical lung cancer.

Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC).

D. Hayes, J. Pierga, S. Nakamura, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.

S. Kopetz, R. Wolff, M. Overman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis.

Q. Hou, H. Wang, F. Fang, 2016, European journal of gynaecological oncology.

Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.

B. Xiu, A. Liang, Y. Qu, 2011, Neoplasma.

Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial.

L. Wang, J. Wang, L. Chen, 2010 .

Abstract P6-17-17: Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)

Junjie Li, Z. Shao, Wei Li, 2019, Poster Session Abstracts.